Evidence map›Paper›PMID 31714895›Full record

Trial reportJCI insight2019

L-Citrulline increases nitric oxide and improves control in obese asthmatics.

Fernando Holguin, Hartmut Grasemann, Sunita Sharma, Daniel Winnica, Karen Wasil, Vong Smith, Margaret H Cruse, Nancy Perez, Erika Coleman, Timothy J Scialla and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01715844 (L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics), which is not on this map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01715844 phase1completednot on this map

L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics

TypeinterventionalSponsorUniversity of PittsburghRan2013 to 2017Enrolled10ConditionsAsthmaArmsL-citrulline
3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Metabolomic and immunological signatures of asthma severity in children.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Article
  10. Article
  11. Article
  12. Obesity: Next game changer of allergic airway diseases?Clinical and translational medicine · 2025
    Review
  13. Non-T2 asthma.Current opinion in pulmonary medicine · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Weight Loss Interventions for Adults With Obesity-Related Asthma.The journal of allergy and clinical immunology. In practice · 2024
    Article
  20. Changes in FeNO, d-ROMs, and BHJournal of asthma and allergy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fernando HolguinDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Hartmut GrasemannDepartment of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
Sunita SharmaDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Daniel WinnicaDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Karen WasilDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Vong SmithDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Margaret H CruseDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Nancy PerezDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Erika ColemanDepartment of Medicine, University of Colorado Medical School, Aurora, Colorado, USA.
Timothy J SciallaDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Loretta G QueDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Funding

SANDIA: Supplementing L-citrulline to overweight late Asthma oNset phenotypes to increase airway L-arginine/ADMA ratio and Improve Asthma controlR01HL146542 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI HOLGUIN, FERNANDO, QUE, LORETTA G · 2019 to 2023
$3.6M
NHLBI NIH HHS R01 HL146542
6 · The paper itself

Abstract

BACKGROUNDThe airways of obese asthmatics have been shown to be NO deficient, and this contributes to airway dysfunction and reduced response to inhaled corticosteroids. In cultured airway epithelial cells, L-citrulline, a precursor of L-arginine recycling and NO formation, has been shown to prevent asymmetric dimethyl arginine-mediated (ADMA-mediated) NO synthase (NOS2) uncoupling, restoring NO and reducing oxidative stress.METHODSIn a proof-of-concept, open-label pilot study in which participants were analyzed before and after treatment, we hypothesized that 15 g/d L-citrulline for 2 weeks would (a) increase the fractional excretion of NO (FeNO), (b) improve asthma control, and (c) improve lung function. To this end, we recruited obese (BMI >30) asthmatics on controller therapy, with a baseline FeNO of ≤30 ppb from the University of Colorado Medical Center and Duke University Health System.RESULTSA total of 41 subjects with an average FeNO of 17 ppb (95% CI, 15-19) and poorly controlled asthma (average asthma control questionnaire [ACQ] 1.5 [95% CI, 1.2-1.8]) completed the study. Compared with baseline, L-citrulline increased whereas ADMA and arginase concentration did not (values represent the mean Δ and 95% CI): plasma L-citrulline (190 μM, 84-297), plasma L-arginine (67 μM, 38-95), and plasma L-arginine/ADMA (ratio 117, 67-167). FeNO increased by 4.2 ppb (1.7-6.7 ppb); ACQ decreased by -0.46 (-0.67 to 0.27 points); the forced vital capacity and forced exhalation volume in 1 second, respectively, changed by 86 ml (10-161 ml) and 52 ml (-11 to 132 ml). In a secondary analysis, the greatest FEV1 increments occurred in those subjects with late-onset asthma (>12 years) (63 ml [95% CI, 1-137]), in females (80 ml [95% CI, 5-154]), with a greater change seen in late-onset females (100 ml, [95% CI, 2-177]). The changes in lung function or asthma control were not significantly associated with the changes before and after treatment in L-arginine/ADMA or FeNO.CONCLUSIONShort-term L-citrulline treatment improved asthma control and FeNO levels in obese asthmatics with low or normal FeNO. Larger FEV1 increments were observed in those with late-onset asthma and in females.TRIAL REGISTRATIONClinicalTrials.gov NCT01715844.FUNDINGNIH NHLBI R01 HL146542-01.

Indexed as

Dietary SupplementsAdultAgedArginineAsthmaCitrullineFemaleForced Expiratory VolumeHumansMaleMiddle AgedNitric OxideNitric Oxide Synthase Type IIObesityOxidative StressPilot ProjectsArginineCitrullineNitric OxideNitric Oxide Synthase Type IIN,N-dimethylarginineNOS2 protein, humanAsthmaPulmonology

Identifiers

PMID31714895
PMCPMC6975256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.